Acta Med. 2002, 45: 145-147
https://doi.org/10.14712/18059694.2019.71
Antiacetylcholinesterase Activity of Cyclosporine – A Comparison of Single and Repeated Administration and Effect of 7-Methoxytacrine
References
1. J, Fusek J, Skopec, F. Changes of cholinesterases in the blood and some tissues following administration of tacrin and its two derivatives to rats. Neurochem Int 1994; 24:555–8.
<https://doi.org/10.1016/0197-0186(94)90007-8>
2. CV, Stahl CE, Keep MF, Elmér E, Watanabe S. Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. Neurosci Lett 2000; 279:73–6.
<https://doi.org/10.1016/S0304-3940(99)00962-3>
3. M, Laplante A, Sepehr-Araé A et al. Inhibition of P-glycoprotein by cyclosporin A analogues and metabolites. Biochem Cell Biol 1999; 77:47–58.
<https://doi.org/10.1139/o99-011>
4. GL, Courtney DK, Andres V, Featherstone RMX. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmac 1961; 7:88–95.
<https://doi.org/10.1016/0006-2952(61)90145-9>
5. L, Racusen L, Fivush B, Solez K, Fisher R. Central nervous system toxicity of cyclosporine in a rat model. Transplantation 1989; 48:316–21.
<https://doi.org/10.1097/00007890-198908000-00025>
6. H, Mašek K. Immunopharmacologic agents in the amelioration of hepatic injuries. Int J Immunopharmacol 1998; 20:125–39.
<https://doi.org/10.1016/S0192-0561(98)00023-X>
7. G, Fahr A. Mechanism of hepatic transport of Cyclosporin A: An explanation for its cholestatic action? Yale J Biol Med 1997; 70:379–90.
8. YM, Moulian N. Cyclosporin A affects functions concerning acetylcholine release of cholinergic Torpedo synaptosomes. Europ J Pharmacol 1996; 296:341–5.
<https://doi.org/10.1016/0014-2999(95)00814-4>
9. J, Bajgar J, Svoboda Z, Květina J, Živný P, Palička V. Effect of acetyl-Lcarnitine on the anticholinesterase activity of 7-methoxytacrine in vivo. Voj Zdrav Listy 2001; 70:87–9.
10. B, Caruso LJ. Prolonged neuromuscular block in a patient undergoing renal transplantation. J Clin Anesthesia 2000; 13:540–4.
<https://doi.org/10.1016/S0952-8180(01)00321-X>
11. J, Braun SV, Reese JC, Guillot A. Cyclosporine-induced white and gray matter central nervous system lesions in a pediatric renal transplant patient. Pediatr Transplantation 1998; 2:45–50.
12. E, Kameníková L, Hynie S, Farghali H. Cyclosporin A modifies cytoplasmic calcium levels in isolated hepatocytes exposed to oxidative stress due to tert-butyl hydroperoxide. Physiol Res 2000; 49:471–4.
13. Y, Asanuma M, Iwata E, Kondo F, Miyzaki I, Ogawa N. Early treatment with cyclosporin A ameliorates the reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurochem Res 1999; 24:9–13.
<https://doi.org/10.1023/A:1020915727119>
14. Krejčová G, Herink J. Současné poznatky o cyklosporinu A. Voj Zdrav Listy 2002; 71(in press).
15. MJ,Lin-Shiau SY. Enhanced spontaneous transmitter release at murine motor nerve terminals with cyclosporine. Neuropharmacol 1999; 38:195–8.
<https://doi.org/10.1016/S0028-3908(98)00178-6>
16. J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66:807–15.
<https://doi.org/10.1016/0092-8674(91)90124-H>
17. YF, Tomizawa K, Moriwaki A et al. Calcineurin inhibitors, FK506 and cyclosporin A, suppress the NMDA receptor-mediated potentials and LTP, but not depotentiation in the rat hippocampus. Brain Res 1996; 729:142–6.
<https://doi.org/10.1016/0006-8993(96)00568-9>
18. ZD, Wang Y, Werlen G, Camp S, Chien KR, Taylor P. Calcineurin enhances acetylcholinesterase mRNA stability during C2-C12 muscle cell differentiation. Mol Pharmacology 1999; 56:886–94.
<https://doi.org/10.1124/mol.56.5.886>
19. Maťha V. Cyclosporin A. Praha: Grada Publishing, 1994:160.
20. SJ, Reinitz ER, Petro G, Schwartz RA. Cyclosporine central neurotoxicity following renal transplantation. Transplantation 1990; 49:215–6.
<https://doi.org/10.1097/00007890-199001000-00048>
